Secure process pumping for biopharm industries
New 620 series pumps provide exceptional levels of performance, accuracy and output for biopharm manufacturers requiring low shear, hygienic fluid handling, with minimal downtime and long term cost savings. Flow rates are up to 18 litre/min and range features a choice of drives, two levels of PIN process protection and minimal downtime.
New 620 series pumps provide exceptional levels of performance, accuracy and output for biopharm manufacturers requiring low shear, hygienic fluid handling, with minimal downtime and long term cost savings. Flow rates are up to 18 litre/min and range features a choice of drives, two levels of PIN process protection and minimal downtime.
The new 620 series represents the next generation in medium sized peristaltic pumps, with market-leading flow rates at pumphead speeds that won't compromise tube life, the pumps have an unrivalled control ratio of 2650:1.
Four drives offer a range of performance levels - from a standard IP31 or IP66 rated pump with manual control, to precision dosing and dispensing applications. The top-of-the range pump within the series, the 620Du, offers exclusive functionality such as automatic analogue and RS485 digital control. Watson-Marlow's unique PIN secure process protection feature means that the 620Du set-up can then be safe-guarded.
Peristaltic pumps have several crucial operational advantages over traditional positive displacement pump designs. The biggest of these is that the pumped media remains contained within the pump tube from source to delivery. This provides obvious benefits in hygienic and sterile applications and where the pumped fluid is of high value.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
